🔎 Trials Near Me

Akèy › Limfom Difize Gwo Selil B › Ohio › Columbus

Etid klinik pou Limfom Difize Gwo Selil B nan Columbus, OH

10 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06649812

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Ap rekriteFaz 1
  • The Ohio State University (OSU), Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Ap rekriteFaz 1/2
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06536049

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Ap rekriteFaz 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Ap rekriteFaz 3
  • The Ohio State University- James Cancer Hospital, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT01804686

DALY II USA/ MB-CART2019.1 for DLBCL

Ap rekriteFaz 2
  • The Ohio State University Wexner Medical Center James Cancer, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Ap rekriteFaz 1
  • The Ohio state University, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05077527

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Ap rekriteFaz 1
  • Ohio State University, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT04775745

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Ap rekriteFaz 1
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Ap rekriteFaz 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2022 · NCT04502394

Etid Limfom Difize Gwo Selil B nan lòt vil

Lòt etid nan Columbus

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.